Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
Jul. 08 | Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours | MT |
Jul. 08 | SANOFI : Jefferies maintains a Buy rating | ZD |
Sales 2024 * | 46.33B 50.13B | Sales 2025 * | 49.75B 53.83B | Capitalization | 115B 125B |
---|---|---|---|---|---|
Net income 2024 * | 7.04B 7.61B | Net income 2025 * | 8.57B 9.27B | EV / Sales 2024 * | 2.64 x |
Net Debt 2024 * | 6.95B 7.52B | Net Debt 2025 * | 2.51B 2.72B | EV / Sales 2025 * | 2.36 x |
P/E ratio 2024 * |
16.6
x | P/E ratio 2025 * |
13.5
x | Employees | - |
Yield 2024 * |
4.2% | Yield 2025 * |
4.42% | Free-Float | 87.13% |
Latest transcript on Sanofi
Managers | Title | Age | Since |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 19-08-31 |
Madeleine Roach
COO | Chief Operating Officer | 40 | 21-12-31 |
Chief Tech/Sci/R&D Officer | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 14-04-30 |
Lise Kingo
BRD | Director/Board Member | 62 | 20-04-27 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 20-05-21 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.48% | 823B | |
-7.18% | 353B | |
+15.37% | 320B | |
+7.45% | 295B | |
+13.62% | 239B | |
+14.55% | 220B | |
-0.33% | 219B | |
+8.14% | 167B | |
-2.99% | 159B |
- Stock Market
- Equities
- SAN Stock
- 0O59 Stock